JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has maintained a Market Outperform rating on Halozyme Therapeutics (NASDAQ:HALO) but lowered the price target from $72 to $71.

May 08, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Halozyme Therapeutics but lowers the price target from $72 to $71.
The adjustment in price target by JMP Securities reflects a slight change in valuation perspective, likely due to updated analysis or market conditions. However, maintaining the Market Outperform rating indicates a continued positive outlook on the company's performance. This could suggest a neutral to slightly positive short-term impact on HALO's stock price, as the market digests the minor adjustment in price target against the backdrop of an overall positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90